SELLAS Life Sciences (SLS) Cash & Equivalents (2010 - 2026)

SELLAS Life Sciences (SLS) reported Cash & Equivalents of $100000.0 for Q1 2026, little changed year-over-year from $100000.0 in Q1 2025, and little changed on a QoQ basis from $100000.0 in Q4 2025.

SELLAS Life Sciences (SLS) has 17 years of Cash & Equivalents data on file, last reported at $100000.0 in Q1 2026.

  • Quarterly Cash & Equivalents changed 0.0% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $100000.0, down 99.28% from the prior year.
  • Cash & Equivalents was little changed at $100000.0 in Q1 2026 per SLS's latest filing, from $100000.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $44.3 million in Q3 2025 and bottomed at $100000.0 in Q1 2022.
  • The 5-year median for Cash & Equivalents is $100000.0 (2022), against an average of $6.3 million.
  • The widest annual swing landed in 2022, when Cash & Equivalents tumbled 99.64%; it then surged 44220.0% in 2025.
  • Tracing SLS's Cash & Equivalents over 5 years: stood at $17.1 million in 2022, then slumped by 85.23% to $2.5 million in 2023, then soared by 448.85% to $13.9 million in 2024, then plunged by 99.28% to $100000.0 in 2025, then changed by 0.0% to $100000.0 in 2026.
  • Per Business Quant, the three latest SLS Cash & Equivalents figures stand at $100000.0 (Q1 2026), $100000.0 (Q4 2025), and $44.3 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 1.91 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - 32.30 Mn
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 286.70 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - 61.46 Mn
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 2.77 Mn
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 5.49 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - 18.44 Mn
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 2.96 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.71 Bn
10 SELLAS Life Sciences 1.61 Bn 1.61 Bn - 100,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 100,000.00
Dec 31, 2025 100,000.00
Sep 30, 2025 44.32 Mn
Jun 30, 2025 100,000.00
Mar 31, 2025 100,000.00
Dec 31, 2024 13.89 Mn
Sep 30, 2024 100,000.00
Jun 30, 2024 100,000.00
Mar 31, 2024 100,000.00
Dec 31, 2023 2.53 Mn
Sep 30, 2023 3.97 Mn
Jun 30, 2023 100,000.00
Mar 31, 2023 23.90 Mn
Dec 31, 2022 17.13 Mn
Sep 30, 2022 100,000.00
Jun 30, 2022 100,000.00
Mar 31, 2022 100,000.00
Dec 31, 2021 21.36 Mn
Sep 30, 2021 26.30 Mn
Jun 30, 2021 100,000.00
Mar 31, 2021 28.00 Mn
Dec 31, 2020 35.30 Mn
Sep 30, 2020 8.20 Mn
Jun 30, 2020 3.30 Mn
Mar 31, 2020 100,000.00
Dec 31, 2019 100,000.00
Sep 30, 2019 115,000.00
Jun 30, 2019 100,000.00
Mar 31, 2019 2.58 Mn
Dec 31, 2018 5.34 Mn
Sep 30, 2018 100,000.00
Jun 30, 2018 8.60 Mn
Mar 31, 2018 8.61 Mn
Dec 31, 2017 12.75 Mn
Sep 30, 2017 12.90 Mn
Jun 30, 2017 13.60 Mn
Mar 31, 2017 18.10 Mn
Dec 31, 2016 6.05 Mn
Sep 30, 2016 24.51 Mn
Jun 30, 2016 19.59 Mn
Mar 31, 2016 401,000.00
Dec 31, 2015 1.40 Mn
Sep 30, 2015 34.71 Mn
Jun 30, 2015 45.28 Mn
Mar 31, 2015 52.86 Mn
Dec 31, 2014 23.65 Mn
Sep 30, 2014 24.65 Mn
Jun 30, 2014 39.16 Mn
Mar 31, 2014 52.43 Mn
Dec 31, 2013 47.79 Mn
Sep 30, 2013 51.40 Mn
Jun 30, 2013 20.92 Mn
Mar 31, 2013 17.48 Mn
Dec 31, 2012 32.81 Mn
Sep 30, 2012 51.40 Mn
Jun 30, 2012 19.23 Mn
Mar 31, 2012 8.70 Mn
Dec 31, 2011 47.79 Mn
Sep 30, 2011 15.69 Mn
Jun 30, 2011 17.93 Mn
Mar 31, 2011 11.12 Mn
Dec 31, 2010 6.89 Mn
Sep 30, 2010 2.84 Mn
Jun 30, 2010 5.09 Mn